利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

10 条记录 (耗时 0.032 秒)

    FLAVIVIRUS-BASED SYSTEM FOR PRODUCTION OF HEPATITIS C VIRUS (HCV)
    4.
    发明申请
    FLAVIVIRUS-BASED SYSTEM FOR PRODUCTION OF HEPATITIS C VIRUS (HCV) 有权
    用于生产乙型肝炎病毒（HCV）的基于FLAVIVIRUS的系统

    公开(公告)号：US20120100574A1

    公开(公告)日：2012-04-26

    申请号：US13122154

    申请日：2009-09-28

    申请人： Bertrand Saunier ,  Miriam Triyatni ,  Edward A. Berger

    发明人： Bertrand Saunier ,  Miriam Triyatni ,  Edward A. Berger

    IPC分类号： C12P21/02 ,  C12N7/02 ,  C12N7/00 ,  C12N5/10 ,  C07K14/18

    CPC分类号： G01N33/5767 ,  C07K14/005 ,  C12N2770/24144 ,  C12N2770/24222 ,  C12N2770/24243

    摘要： Provided herein is a mammalian cell transformed to contain a plasmid encoding a T7 or SP6 promoter operably linked to one or more HCV genes, a subgenomic replicon from a flavivirus and a cytoplasmic T7 and SP6 RNA amplification system. Also provided herein are isolated replication-competent HCV particles produced by the method comprising the steps of providing a transformed mammalian cell according to the first embodiment, culturing the cell, and recovering the replication-competent HCV particles from the cell culture. Provided herein are isolated HCV structural proteins produced by the method comprising the steps of providing a transformed mammalian cell according to the first embodiment, culturing the cell, and recovering the HCV structural proteins from the cell culture. Further provided herein is a system for assaying HCV entry into a cell comprising a first plasmid encoding a T7 or SP6 promoter operably linked to an HCV polynucleotide comprising at least the 5′-UTR to NS2 operably linked to an EMCV IRES in frame with an SP6 or T7 polymerase gene, respectively, a first host cell line expressing a replicon from a flavivirus and comprising a cytoplasmic T7 and SP6 RNA amplification system, a second plasmid encoding a reporter gene operably linked to both T7 and SP6 promoters in tandem, and a second host cell line comprising a cytoplasmic T7 polymerase or SP6 polymerase RNA amplification system.

    摘要翻译： 本文提供了转化成含有编码与一种或多种HCV基因可操作地连接的T7或SP6启动子的质粒的哺乳动物细胞，来自黄病毒的亚基因组复制子和细胞质T7和SP6 RNA扩增系统。 本文还提供了通过包括以下步骤的方法产生的分离的可复制的HCV颗粒，所述方法包括提供根据第一实施方案的转化的哺乳动物细胞，培养细胞，以及从细胞培养物中回收可复制的HCV颗粒。 本文提供了通过包括以下步骤的方法产生的分离的HCV结构蛋白，所述方法包括提供根据第一实施方案的转化的哺乳动物细胞，培养细胞，以及从细胞培养物中回收HCV结构蛋白。 本文进一步提供用于测定HCV进入细胞的系统，其包含编码T7或SP6启动子的第一质粒，所述第一质粒可操作地连接至包含至少5'- UTR至NS2的HCV多核苷酸，其可操作地连接到具有SP6的框架的EMCV IRES 或T7聚合酶基因，表达来自黄病毒的复制子的第一宿主细胞系，其包含细胞质T7和SP6RNA扩增系统，编码与T7和SP6启动子串联可操作地连接的报告基因的第二质粒和第二个 包含细胞质T7聚合酶或SP6聚合酶RNA扩增系统的宿主细胞系。

    CC CHEMOKINE RECEPTOR 5 DNA, NEW ANIMAL MODELS AND THERAPEUTIC AGENTS FOR HIV INFECTION
    5.
    发明申请
    CC CHEMOKINE RECEPTOR 5 DNA, NEW ANIMAL MODELS AND THERAPEUTIC AGENTS FOR HIV INFECTION 审中-公开
    CC CHEMOKINE RECEPTOR 5 DNA，新动物模型和艾滋病毒感染治疗剂

    公开(公告)号：US20110117101A1

    公开(公告)日：2011-05-19

    申请号：US13012482

    申请日：2011-01-24

    申请人： Christophe Combadiere ,  Philip M. Murphy ,  Edward A. Berger

    发明人： Christophe Combadiere ,  Philip M. Murphy ,  Edward A. Berger

    IPC分类号： A61K39/395 ,  A61P31/18 ,  C12N5/071

    CPC分类号： C07K14/7158 ,  A01K2217/05 ,  A61K38/00

    摘要： The susceptibility of human macrophages to human immunodeficiency virus (HIV) infection depends on cell surface expression of the human CD4 molecule and CC cytokine receptor 5. CCR5 is a member of the 7-transmembrane segment superfamily of G-protein-coupled cell surface molecules. CCR5 plays an essential role in the membrane fusion step of infection by some HIV isolates. The establishment of stable, nonhuman cell lines and transgenic mammals having cells that coexpress human CD4 and CCR5 provides valuable tools for the continuing research of HIV infection. In addition, antibodies which bind to CCR5, CCR5 variants, and CCR5-binding agents, capable of blocking membrane fusion between HIV and target cells represent potential anti-HIV therapeutics for macrophage-tropic strains of HIV.

    摘要翻译： 人类巨噬细胞对人类免疫缺陷病毒（HIV）感染的易感性取决于人CD4分子和CC细胞因子受体5的细胞表面表达。CCR5是G蛋白偶联细胞表面分子的7-跨膜段超家族的成员。 CCR5在一些HIV分离物感染的膜融合步骤中起着重要作用。 建立稳定的非人细胞系和具有共表达人CD4和CCR5的细胞的转基因哺乳动物为继续研究艾滋病毒感染提供了宝贵的工具。 此外，结合CCR5，CCR5变体和CCR5结合剂的能够阻断HIV和靶细胞之间的膜融合的抗体代表了HIV巨噬细胞趋化株的潜在的抗HIV治疗剂。

    Flavivirus-based system for production of hepatitis C virus (HCV)
    6.
    发明授权
    Flavivirus-based system for production of hepatitis C virus (HCV) 有权
    用于生产丙型肝炎病毒（HCV）的基于黄病毒病毒的系统

    公开(公告)号：US09052321B2

    公开(公告)日：2015-06-09

    申请号：US13122154

    申请日：2009-09-28

    申请人： Bertrand Saunier ,  Miriam Triyatni ,  Edward A. Berger

    发明人： Bertrand Saunier ,  Miriam Triyatni ,  Edward A. Berger

    IPC分类号： C12N5/10 ,  C12N15/85 ,  G01N33/68 ,  C12Q1/68 ,  G01N33/576 ,  C07K14/005

    CPC分类号： G01N33/5767 ,  C07K14/005 ,  C12N2770/24144 ,  C12N2770/24222 ,  C12N2770/24243

    摘要： Provided herein is a mammalian cell transformed to contain a plasmid encoding a T7 or SP6 promoter operably linked to one or more HCV genes, a subgenomic replicon from a flavivirus and a cytoplasmic T7 and SP6 RNA amplification system. Also provided herein are isolated replication-competent HCV particles produced by the method comprising the steps of providing a transformed mammalian cell according to the first embodiment, culturing the cell, and recovering the replication-competent HCV particles from the cell culture. Provided herein are isolated HCV structural proteins produced by the method comprising the steps of providing a transformed mammalian cell according to the first embodiment, culturing the cell, and recovering the HCV structural proteins from the cell culture. Further provided herein is a system for assaying HCV entry into a cell comprising a first plasmid encoding a T7 or SP6 promoter operably linked to an HCV polynucleotide comprising at least the 5′-UTR to NS2 operably linked to an EMCV IRES in frame with an SP6 or T7 polymerase gene, respectively, a first host cell line expressing a replicon from a flavivirus and comprising a cytoplasmic T7 and SP6 RNA amplification system, a second plasmid encoding a reporter gene operably linked to both T7 and SP6 promoters in tandem, and a second host cell line comprising a cytoplasmic T7 polymerase or SP6 polymerase RNA amplification system.

    摘要翻译： 本文提供了转化成含有编码与一种或多种HCV基因可操作地连接的T7或SP6启动子的质粒的哺乳动物细胞，来自黄病毒的亚基因组复制子和细胞质T7和SP6 RNA扩增系统。 本文还提供了通过包括以下步骤的方法产生的分离的可复制的HCV颗粒，所述方法包括提供根据第一实施方案的转化的哺乳动物细胞，培养细胞，以及从细胞培养物中回收可复制的HCV颗粒。 本文提供了通过包括以下步骤的方法产生的分离的HCV结构蛋白，所述方法包括提供根据第一实施方案的转化的哺乳动物细胞，培养细胞，以及从细胞培养物中回收HCV结构蛋白。 本文进一步提供用于测定HCV进入细胞的系统，其包含编码T7或SP6启动子的第一质粒，所述第一质粒可操作地连接至包含至少5'- UTR至NS2的HCV多核苷酸，其可操作地连接到具有SP6的框架的EMCV IRES 或T7聚合酶基因，表达来自黄病毒的复制子的第一宿主细胞系，其包含细胞质T7和SP6RNA扩增系统，编码与T7和SP6启动子串联可操作地连接的报告基因的第二质粒和第二个 包含细胞质T7聚合酶或SP6聚合酶RNA扩增系统的宿主细胞系。

    Chimeric protein for prevention and treatment of HIV infection
    10.
    发明授权
    Chimeric protein for prevention and treatment of HIV infection 失效
    用于预防和治疗HIV感染的嵌合蛋白

    公开(公告)号：US08420099B2

    公开(公告)日：2013-04-16

    申请号：US11535957

    申请日：2006-09-27

    申请人： Edward A. Berger ,  Christie M. Del Castillo

    发明人： Edward A. Berger ,  Christie M. Del Castillo

    IPC分类号： A61K39/21 ,  C07H21/02 ,  C07H21/04 ,  C07K14/00 ,  C07K16/08 ,  C07K16/42

    CPC分类号： C07K16/1045 ,  A61K39/395 ,  Y10S435/975

    摘要： This invention relates to bispecific fusion proteins effective in viral neutralization. More specifically, such proteins have two different binding domains, an inducing-binding domain and an induced-binding domain, functionally linked by a peptide linker. Such proteins, nucleic acid molecules encoding them, and their production and use in preventing or treating viral infections are provided. One prototypical bispecific fusion protein is sCD4-SCFv(17b), in which a soluble CD4 fragment (containing domains D1 and D2) is fused to a single chain Fv portion of antibody 17b via a linker.

    摘要翻译： 本发明涉及在病毒中和中有效的双特异性融合蛋白。 更具体地，这样的蛋白质具有两个不同的结合结构域，即通过肽接头功能连接的诱导结合结构域和诱导结合结构域。 提供了这样的蛋白质，编码它们的核酸分子及其在预防或治疗病毒感染中的生产和用途。 一种原型双特异性融合蛋白是sCD4-SCFv（17b），其中可溶性CD4片段（含有结构域D1和D2）通过接头与抗体17b的单链Fv部分融合。